<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">Problems of Social Hygiene, Public Health and History of Medicine</journal-id><journal-title-group><journal-title>Problems of Social Hygiene, Public Health and History of Medicine</journal-title></journal-title-group><issn publication-format="print">0869-866X</issn><issn publication-format="electronic">2412-2106</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2614</article-id><article-id pub-id-type="doi">10.32687/0869-866X-2026-34-2-322-329</article-id><article-categories><subj-group subj-group-type="heading"><subject>Научная статья</subject></subj-group></article-categories><title-group><article-title>THE HISTORY OF PHARMACEUTICAL LAW. REPORT III. THE TRENDS OF GLOBALIZATION OF REGULATIVE NORMS IN XXI CENTURY</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Volskaya</surname><given-names>E. A.</given-names></name><email></email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia</aff><pub-date date-type="epub" iso-8601-date="2026-04-21" publication-format="electronic"><day>21</day><month>04</month><year>2026</year></pub-date><volume>34</volume><issue>2</issue><fpage>322</fpage><lpage>329</lpage><history><pub-date date-type="received" iso-8601-date="2026-04-22"><day>22</day><month>04</month><year>2026</year></pub-date></history><permissions><copyright-statement>Copyright © 2026,</copyright-statement><copyright-year>2026</copyright-year></permissions><abstract>This article continues the cycle of publications on the study of history of pharmaceutical law. In the XXI century, the third stage of development of regulation of pharmaceutical sphere began. The introduction of the laws of direct action or regulations, completed the process of harmonization of European regulatory norms with American ones. The implementation of the rules of good practices of research and production of ICH into legislation of countries with developed market of medicinal products ensured unification of technical requirements to safety and quality of medications in the general pharmaceutical market.</abstract><kwd-group xml:lang="en"><kwd>pharmaceutical law</kwd><kwd>medicinal product</kwd><kwd>the law</kwd><kwd>regulation</kwd><kwd>harmonization</kwd><kwd>historical development.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>фармацевтическое право</kwd><kwd>лекарственное средство</kwd><kwd>закон</kwd><kwd>регулирование</kwd><kwd>гармонизация</kwd><kwd>историческое развитие.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Вольская Е. А. Развитие регулирования в сфере обращения лекарственных средств в ЕС и США в 1992-2020 гг. Сообщение 2. Формирование нормативно-правовой базы сферы обращения лекарственных средств в Европейском Союзе в 1992—2001 гг. Проблемы социальной гигиены, здравоохранения и истории медицины. 2024;32(4):772—7.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Лиддел-Гарт Б. Г. Стратегия непрямых действий. М.: Издательство АКТ; 2017. 508 с.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Вольская Е. А. Развитие регулирования в сфере обращения лекарственных средств в ЕС и США в 1992—2020 гг. Сообщение 3. Формирование законодательства Европейского союза в сфере обращения лекарственных средств в 2001—2020 гг. Проблемы социальной гигиены, здравоохранения и истории медицины. 2024;32(5):933—40.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>A pharmaceutical strategy for Europe. Health &amp;amp; Food safety Newsletters. Режим доступа: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe_en</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Anwendungsvorrang des Unionsrechts. Kurzinformation. Deutscher Bundestag. Wissenschaftliche Dienste. Режим доступа: https://www.bundestag.de/resource/blob/817832/ceb32e6ab9ef804dda3902ad65800ab5/WD-3-263-20-pdf.pdf</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Regulation 2017/556 of 24 March 2017 on the detailed arrangements for the good clinical practice inspection procedures pursuant to Regulation (EU) No 536/2014 of the European Parliament and of the Council. Offic. J. Eur. Union. 2017;L80:7—13.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Regulation 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Offic. J. Eur. Union. 2000;L18:1—5.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Regulation 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. Offic. J. Eur. Union. 2006;L378:1—19.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Regulation 726/2004 of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Offic. J. Eur. Union. 2004;L136:1—32.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Members &amp;amp; Observers. Режим доступа: https://www.ich.org/page/members-observers</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Molzon J. A. The Value and Benefits of the International Conference on Harmonisation (ICH) to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health. In: van der Laan J., DeGeorge J. (eds). Global Approach in Safety Testing. AAPS Advances in the Pharmaceutical Sciences Series. V. 5. New York: Springer; 2013. P. 23—7.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ramnarayanan Ch. A history of ICH guidelines: Inside the regulatory revolution that reshaped pharmaceutical development. Режим доступа: https://www.jmp.com/en/blog/health-and-life-sciences/</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>ICH Harmonised Guideline. Organisation of the Common Technical Document for the Registration of Pharmaceuticals for human use M4. Current Step 4 version dated June 15, 2016. Режим доступа: https://database.ich.org/sites/default/files/M4_R4__Guideline.pdf</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Pharmaceutical Inspection Co-operation Scheme. PIC/S 1/95 (Rev. 6) 12 November 2019. Режим доступа: https://picscheme.org/docview/2147</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>List of PIC/S participating authorities. Режим доступа: https://picscheme.org/en/members</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Завершено подписание исторического договора о взаимном признании между FDA и EMA. Режим доступа: https://chemrar.ru/zaversheno-podpisanie-istoricheskogo-dogovora-o-vzaimnom-priznanii-mezhdu-fda-i-ema/</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Акты Евразийской экономической комиссии. Режим доступа: https://docs.eaeunion.org/documents/306/</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Фотеева А. В., Баршадская О. С., Ростова Н. Б. Процедура взаимного признания при регистрации лекарственных препаратов: новые вызовы или возможности. Разработка и регистрация лекарственных средств. 2022;11(1):159—64.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Решение Совета Евразийской экономической комиссии от 3 ноября 2016 года №78 «О Правилах регистрации и экспертизы лекарственных средств для медицинского применения». Режим доступа: https://docs.cntd.ru/document/456026097#7DC0K7</mixed-citation></ref></ref-list></back></article>
